Il36g, also known as interleukin 36 gamma, is a cytokine that plays a significant role in immune-related biological processes. It is involved in inflammatory responses and is associated with pathways such as the IL-23/IL-17 axis, which is crucial in psoriasis pathology [4].

In psoriasis, studies have shown various relationships related to Il36g. The expression of Il36g in keratinocytes follows an inverse pattern to that of PCSK9, with Il36g expression highest in granular layer keratinocytes [1]. Genetic variants of Il36g are associated with psoriasis susceptibility, severity, and joint involvement. For example, the G allele of the Il36g rs7584409 variant has a protective effect against psoriasis, but in patients with psoriasis, it is associated with moderate-to-severe disease and psoriatic arthritis [3]. Polymorphisms in the Il36g gene are also associated with plaque psoriasis, potentially affecting the functionality of the IL-36γ cytokine [4].

In cancer, IL36G-producing neutrophil-like monocytes, called cachexia-inducible monocytes (CiMs), promote skeletal muscle loss in cachexia, and genetic inhibition of IL36G-mediated signaling attenuates this muscle loss [2].

In conclusion, Il36g is a cytokine with a notable role in inflammatory and immune-related processes, especially in diseases like psoriasis and cancer cachexia. Studies on Il36g, including those using genetic models to understand its variants and functions, have provided insights into the pathogenesis of these diseases, which may help in developing new therapeutic strategies for these conditions.